Caxton Associates (New York)’s BlueLinx BXC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-10,632
Closed -$1.38M 485
2024
Q1
$1.38M Sell
10,632
-1,381
-11% -$162K 0.08% 177
2023
Q4
$1.36M Buy
+12,013
New +$1.04M 0.07% 182
2023
Q3
Sell
-5,406
Closed -$507K 420
2023
Q2
$507K Buy
+5,406
New +$432K 0.08% 267
2022
Q2
Sell
-3,429
Closed -$246K 577
2022
Q1
$246K Sell
3,429
-3,048
-47% -$250K 0.02% 397
2021
Q4
$620K Buy
+6,477
New +$439K 0.06% 223

Other funds holding BXC

Caxton Associates (New York)'s BXC Position: Q2 2024 in Review

Caxton Associates (New York) sold out of BlueLinx (BXC) in Q2 2024, closing a stake of 10,632 shares — an estimated $1.38M sold.

Caxton Associates (New York) first reported a position in BXC in Q4 2021 and held it in 5 quarters. The position peaked at $1.38M in Q1 2024. 168 funds tracked by Wall St. Rank hold BXC as of Q2 2024.

  • Caxton Associates (New York) reported no remaining BlueLinx position as of Q2 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 10,632 BlueLinx shares in Q2 2024, an estimated $1.38M.
  • Caxton Associates (New York) first reported a position in BlueLinx in Q4 2021 and held it in 5 quarters.
  • Caxton Associates (New York)'s BlueLinx position peaked at $1.38M in Q1 2024.
  • 168 funds tracked by Wall St. Rank held BlueLinx as of Q2 2024.

Based on Caxton Associates (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.